PE20091022A1 - Anticuerpos anti-factor b y sus usos - Google Patents

Anticuerpos anti-factor b y sus usos

Info

Publication number
PE20091022A1
PE20091022A1 PE2008001904A PE2008001904A PE20091022A1 PE 20091022 A1 PE20091022 A1 PE 20091022A1 PE 2008001904 A PE2008001904 A PE 2008001904A PE 2008001904 A PE2008001904 A PE 2008001904A PE 20091022 A1 PE20091022 A1 PE 20091022A1
Authority
PE
Peru
Prior art keywords
factor
antibody
humanized
diabetic
life chain
Prior art date
Application number
PE2008001904A
Other languages
English (en)
Inventor
Menno Van Lookeren Campagne
Laura Deforge
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091022(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20091022A1 publication Critical patent/PE20091022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDO A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO 1F7 ANTI-FACTOR B, MONOCLONAL QUIMERICO O HUMANIZADO, EL CUAL SE UNE A UN EPITOPE QUE INCLUYE RESIDUOS DE SITIOS ACTIVOS DEL FACTOR B, Y QUE COMPRENDE LAS SECUENCIAS DE REGION HIPERVARIABLE DE CADENA LIVIANA Y/O PESADA SEGUN SEC ID N°: 1 Y 2 RESPECTIVAMENTE. DICHO ANTICUERPO ES UTIL PARA EL TRATAMIENTO DE AFECCIONES OCULARES ASOCIADAS CON EL COMPLEMENTO, TALES COMO NEOVASCULARIZACION COROIDAL, DEGENERACION MACULAR RELACIONADA CON LA EDAD, RETINOPATIAS DIABETICAS, EDEMA MACULAR DIABETICO, MIOPIA PATOLOGICA
PE2008001904A 2007-11-08 2008-11-07 Anticuerpos anti-factor b y sus usos PE20091022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08

Publications (1)

Publication Number Publication Date
PE20091022A1 true PE20091022A1 (es) 2009-07-16

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001904A PE20091022A1 (es) 2007-11-08 2008-11-07 Anticuerpos anti-factor b y sus usos

Country Status (15)

Country Link
US (4) US8158762B2 (es)
EP (1) EP2209807A1 (es)
JP (1) JP2011503094A (es)
KR (1) KR20100105587A (es)
CN (1) CN101918444A (es)
AR (1) AR069233A1 (es)
AU (1) AU2008323939A1 (es)
BR (1) BRPI0820343A2 (es)
CA (1) CA2704973A1 (es)
CL (1) CL2008003313A1 (es)
IL (1) IL205577A0 (es)
MX (1) MX2010005115A (es)
PE (1) PE20091022A1 (es)
TW (1) TW200927170A (es)
WO (1) WO2009061910A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2453906A4 (en) 2009-07-02 2014-01-15 Musc Found For Res Dev METHOD FOR STIMULATING THE LIVER REGENERATION
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
EP2855529A4 (en) * 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
CR20180529A (es) 2016-04-04 2019-03-21 Bioverativ Usa Inc Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CA3173325A1 (en) 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
ES2527695T3 (es) * 2006-03-08 2015-01-28 Archemix Llc Aptámeros de unión a complemento y agentes anti-C5 útiles en el tratamiento de trastornos oculares
US20100120665A1 (en) 2007-03-01 2010-05-13 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation

Also Published As

Publication number Publication date
US20160024224A1 (en) 2016-01-28
CN101918444A (zh) 2010-12-15
JP2011503094A (ja) 2011-01-27
AR069233A1 (es) 2010-01-06
IL205577A0 (en) 2010-11-30
WO2009061910A1 (en) 2009-05-14
US20180037667A1 (en) 2018-02-08
KR20100105587A (ko) 2010-09-29
AU2008323939A1 (en) 2009-05-14
US8158762B2 (en) 2012-04-17
TW200927170A (en) 2009-07-01
US20120230997A1 (en) 2012-09-13
EP2209807A1 (en) 2010-07-28
US20090123469A1 (en) 2009-05-14
BRPI0820343A2 (pt) 2017-08-22
CL2008003313A1 (es) 2010-02-05
MX2010005115A (es) 2010-05-27
CA2704973A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
PE20091022A1 (es) Anticuerpos anti-factor b y sus usos
PE20190389A1 (es) Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
DOP2014000007A (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada
BR112014008759A2 (pt) tratamento de doença ocular
PH12020552178A1 (en) Anti-il36r antibodies
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20200734A1 (es) Anticuerpos anti-tgf-beta y su uso
UY37290A (es) Anticuerpos anti-ige
CN106062206A (zh) 双特异性cd3和cd19抗原结合构建体
PE20161440A1 (es) Variantes del anticuerpo anti-factor d y sus usos
PE20080119A1 (es) Anticuerpos anti-5ta y sus usos
PE20190907A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
AR080026A1 (es) Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4)
MA40182A (fr) NOUVEL ANTICORPS ANTI-Tie2 HUMAIN
PE20191347A1 (es) Anticuerpos procoagulantes
PE20141560A1 (es) Anticuerpo anti-epirregulina humanizado y agente terapeutico contra el cancer que comprende dicho anticuerpo como ingrediente activo
PE20140448A1 (es) Moleculas de union biespecificas que se unen a vegf y ang2
PE20081478A1 (es) Anticuerpos cd44
ECSP099379A (es) Anticuerpos anti-factor d humanizados
PE20211786A1 (es) Anticuerpos humanizados contra c-kit
EA201391812A1 (ru) Отдельные вариабельные домены против vegf, слитые с fc-доменами
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
EP2581113A4 (en) ANTI-TIM-3 ANTIBODIES

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed